Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial

Kayla Ward, Vivien Li, Sudarshini Ramanathan, Lesley-Ann Hall, Katherine Buzzard, Kaylene Young, Fiona Mckay, Vanessa Vigar, Sabrina Oishi, Lidia Madrid San Martin, Belinda Kaskow, Grant Parnell, Julie A Campbell, Jing Sun, Corey Smith, Vilija Jokubaitis, Tomas Kalincik, David Tscharke, Andrew Potte · 2025

Read Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial by Kayla Ward, Vivien Li, Sudarshini Ramanathan, Lesley-Ann Hall, Katherine Buzzard, Kaylene Young, Fiona Mckay, Vanessa Vigar, Sabrina Oishi, Lidia Madrid San Martin, Belinda Kaskow, Grant Parnell, Julie A Campbell, Jing Sun, Corey Smith, Vilija Jokubaitis, Tomas Kalincik, David Tscharke, Andrew Potte (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12730750.txt.

Description

Kayla Ward and a large Australian consortium publish the protocol for STOP-MS, a trial testing two repurposed drugs against progressive multiple sclerosis, in a 2025 paper. Progressive disease is the field's biggest unmet need, and evidence tying the Epstein-Barr virus to MS makes antiviral therapy a root-cause bet. The two candidates are spironolactone and famciclovir.

The multi-arm, multi-stage trial randomizes patients aged twenty-five to seventy with established disability, double-blind against placebo. Stage one, with 150 participants, asks whether the drugs cut virus DNA in saliva and antibody levels by at least ten percent. Stage two, with 300, measures confirmed disability progression over six months. Recruitment began in March 2025, and the first participant enrolled that April. The protocol is registered in Australia and New Zealand. Its staged design lets weak candidates fail early and cheaply.

Catalog record

CREATORKayla Ward, Vivien Li, Sudarshini Ramanathan, Lesley-Ann Hall, Katherine Buzzard, Kaylene Young, Fiona Mckay, Vanessa Vigar, Sabrina Oishi, Lidia Madrid San Martin, Belinda Kaskow, Grant Parnell, Julie A Campbell, Jing Sun, Corey Smith, Vilija Jokubaitis, Tomas Kalincik, David Tscharke, Andrew Potte
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE62 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12730750

Browse the full library · About the Tower of Babel